New Content  edit
Get The App!

An Interactive CME/CNE Certified Virtual Symposium

An Interactive CME/CNE Certified Virtual Symposium

Holding Court in Pulmonary Hypertension: Should SSc-PAH Patients Receive Up-front Triple Therapy Upon Diagnosis? You Decide the Verdict to Better Outcomes

Join the Live Event
Sign In Required

Broadcast Live on MedEd OTG:

Sunday, October 18, 2020

5:30 - 6:30pm CDT

This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.

Symposium Overview

The program is designed around a court case pro/con debate concept. Faculty act as the judge, attorneys, and witnesses, enabling the clinicians to present both sides of a controversial issue to allow the audience to fully understand the complexities of the issue. The audience serves as the jury and will vote to determine the final verdict. This program will examine whether all newly diagnosed scleroderma patients with confirmed PAH should receive up-front triple therapy. Combination therapy for newly diagnosed PAH patients is becoming standard of care based on recent large event-driven clinical trials but the high-risk scleroderma-PAH patient may require management above and beyond that needed for the idiopathic PAH patient. This debate will serve to focus the audience on the issue and explore the essentials of managing these high-risk patients.

Faculty

Richard Channick, MD (Judge)

Professor of Medicine Division of Pulmonary and Critical Care Medicine David Geffen School of Medicine at UCLA, Los Angeles, CA

Rajan Saggar, MD (Attorney-Pro)

Professor of Medicine Co-Director, Pulmonary Vascular Disease Program Co-Director, Medical Intensive Care Unit Lung & Heart-Lung Transplant and Pulmonary Hypertension Programs David Geffen School of Medicine UCLA Medical Center, Los Angeles, CA

Jean Elwing, MD (Attorney-Con)

Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine Director, Pulmonary Hypertension Program University of Cincinnati, Cincinnati, OH

Ioana Preston, MD (Witness)

Associate Professor of Medicine Tufts University School of Medicine Director, Pulmonary Hypertension Center Director, Pulmonary Function Test Lab Pulmonary, Critical Care and Sleep Division Tufts Medical Center, Boston, MA

Victor Tapson, MD (Witness)

Professor of Medicine Division of Pulmonary & Critical Care Cedars-Sinai Medical Center, Los Angeles, CA

Full Accreditation and Program Information

Agenda

5:30 pm
Welcome, Overview & Opening Scene: Introduction to the virtual courtroom concept & judge, prosecutor & defense opening remarks on the case topic
5:40 pm
Prosecutor examines witness & defense cross examines witness
5:55 pm
Defense attorney examines witness and prosecutor cross examines witness
6:10 pm
Attorney Closing arguments
6:20 pm
Judge concludes case and refers verdict determinization to the audience (jurors)
6:25 pm
Verdict is read with live Q.A to follow
6:30 pm
Adjourn

Target Audience

This activity has been designed to meet the educational needs of physicians, registered nurses and other healthcare professionals involved in the care of patients with pulmonary hypertension.

Learning Objectives

After completing this activity, the participant should be better able to:

  1. Evaluate New WHO Proceeding recommendations for non-Group 1 PH
  2. Identify issues surrounding variants of PH and incorporate current clinical trials further examining disease etiology
  3. Assess current practice guidelines and updates for CTEPH, specifically regarding treatment goals
  4. Discuss issues surrounding CTEPH and highlight current medical and surgical interventions
  5. Review recent or ongoing clinical trials examining non-Group 1 pulmonary hypertension or studies of non-idiopathic Group 1 PH

Exclusive! Pre and Post-Meeting Content

Experience a new way to learn. Receive pre-meeting content and post-meeting quizzes to enhance your learning experience. Register now to access exclusive content and fully experience the benefits of this interactive program.

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and TotalCME. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation
1.0 contact hour may be earned for successful completion of this activity.

Disclosure of Conflicts of Interest

The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Fee Information: There is no fee for this educational activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within three weeks.

Annenberg
TotalCME
PIM

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and TotalCME in collaboration with Postgraduate Institute for Medicine.

Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson